Thomas Niel

Thomas Niel

InvestorPlace Contributor

Expertise: Micro-Cap Stocks, Shareholder Activist Stocks, Value Stocks

Education: Bachelors in Accounting, CFA Program Participant (Completed Level I in 2017)

About Thomas:
Thomas Niel is an investment writer at InvestorPlace. With a professional background in accounting and financial analysis, his understanding of both words and figures pays dividends when writing clear, concise stock analysis.

A value investor at heart, Thomas looks at the fundamentals. Peer analysis and earnings multiples rarely tell the whole story. But, Thomas believes valuation metrics are a great starting point to separate the wheat from the chaff.

His work has appeared at several websites, including Seeking Alpha and TipRanks. Outside of investment research, Thomas provides inbound marketing content to the investment management industry.

You can follow Thomas on Twitter and check out his track record on TipRanks.

Recent Articles

5 High-Yield MLPs Worth a Look This Fall

By Thomas Niel, InvestorPlace Contributor

It may not be for several years energy stocks retrace their pre-pandemic price levels. But, with high-yields while you wait, and the opportunity for long-term upside, consider these five MLPs as we enter the fall.

Scant Vaccine Hopes Aren’t Enough to Make iBio a Buy

By Thomas Niel, InvestorPlace Contributor

As I detailed earlier this month, there are many pandemic vaccine plays out there with greater chances of success. That's not to say these rival candidates will find success. But, compared to IBIO stock, they look like worthwhile wagers.

Nio Stock May Be Crushing It, But It’s Time to Sell

By Thomas Niel, InvestorPlace Contributor

So, what's the play here? If you bought in at lower prices, it may be time to cash out. And if you missed the boat a few month's back? Don't try to play catchup by entering a position today, as shares remain "priced for perfection."

Novavax Stock Definitely Is Not the Long-Shot Vaccine Play You Might Think

By Thomas Niel, InvestorPlace Contributor

Bottom line: don't bet the ranch, but NVAX stock is a buy as it enters Phase 3 trials.

Jumia Stock Is Worth a Look, But Tread Carefully

By Thomas Niel, InvestorPlace Contributor

That being said, after the August sell-off, the odds may be more in your favor now than before with long-shot JMIA stock. Don't bet the ranch, but there's still opportunity here.

Load More